{'fraction_non_alphanumeric': 0.02854122621564482, 'fraction_numerical': 0.009513742071881607, 'mean_word_length': 4.993670886075949, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Trimethoprim-sulfamethoxazole therapy for Pneumocystis carinii pneumonitis in children.

Trimethoprim-sulfamethoxazole (TMP-SMZ) is effective in both the treatment and the prevention of Pneumocystis carinii pneumonitis. After initial evaluation in an animal model, TMP-SMZ was shown to be as clinically effective as pentamidine isethionate for the treatment of pneumonitis in children with cancer and to have minimal adverse effects. Treatment with TMP-SMZ (20 mg of TMP and 100 mg of SMZ per kg of body weight per day) was successful in three-fourths of patients tested. Administered prophylactically, TMP-SMZ (5.0 mg of TMP and 25 mg of SMZ per kg of body weight per day) prevented P. carinii infection in high-risk immunocompromised patients. Studies of the unstructured delivery of prophylactic TMP-SMZ have demonstrated the regimen to be feasible and effective, with a favorable benefit-risk ratio for a large number of children with cancer.